Fluoroquinolonas

Detalhes bibliográficos
Autor(a) principal: Morais Almeida, Maria da Graça
Data de Publicação: 1994
Outros Autores: Machado, Maria José
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://revista.spmi.pt/index.php/rpmi/article/view/2471
Resumo: Fluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mecha­nism of action involves inhibition of bacterial DNA­ girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudo­monas aeruginosa and Staphilococcus sp., howe­ver recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The inci­dence of adverse effects to fluoroquinolones appe­ars to be low. The most common are gastrointesti­ nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occa­sionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifesta­tions, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of effi­cacity, when compared with IV administration, thus reducing substantially the treatment cost.
id RCAP_65b88cd44f9c92a09e04ad31941f326b
oai_identifier_str oai:oai.revista.spmi.pt:article/2471
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Fluoroquinolonasfluoroquinolonasantimicrobia­nosnorfloxacinaciprofloxacinaofloxacinapefloxacinafluoroquinolonesantimicrobialsnorfloxacinofloxacinpefloxacinciprofloxacinFluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mecha­nism of action involves inhibition of bacterial DNA­ girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudo­monas aeruginosa and Staphilococcus sp., howe­ver recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The inci­dence of adverse effects to fluoroquinolones appe­ars to be low. The most common are gastrointesti­ nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occa­sionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifesta­tions, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of effi­cacity, when compared with IV administration, thus reducing substantially the treatment cost.As fluoroquinolonas são compostos sintéticos quimicamente relacionados com o ácido nalidíxi­co. Embora não estando ainda bem esclarecido o mecanismo de acção, pensa-se que actuam inibin­do a DNA-girase. São agentes antimicrobianos de largo espectro, possuindo elevada actividade con­tra Enterobacteriáceas. São activas contra algu­mas estirpes de Pseudomonas aeruginosa e Estafilococus sp.,contudo bibliografia recente refere aumento de resistências. Tem actividade reduzida contra Streptococcus e anaeróbios. São bem absor­vidas por via oral, apresentando uma boa distri­buição tecidular, excretando-se preferencialmen­te por via renal. São fármacos seguros com pou­cos efeitos secundários, sendo os mais frequentes os gastrointestinais, algumas alterações a nível do S.N.C. e mais raramente reacções de hipersensibi­lidade. As interacções com alguns medicamentos nomeadamente antiácidos, teofilina e varfarina podem ter algum significado clínico. A biodisponi­bilidade das fluoroquinolonas permite a sua administração por via oral sem perda de eficácia terapêutica, quando comparadas com administra­ção IV, reduzindo assim substancialmente os cus­tos de tratamento.Sociedade Portuguesa de Medicina Interna1994-09-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spmi.pt/index.php/rpmi/article/view/2471Internal Medicine; Vol. 1 No. 3 (1994): Julho/ Setembro; 189-192Medicina Interna; Vol. 1 N.º 3 (1994): Julho/ Setembro; 189-1922183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/2471https://revista.spmi.pt/index.php/rpmi/article/view/2471/1816Direitos de Autor (c) 1994 Medicina Internainfo:eu-repo/semantics/openAccessMorais Almeida, Maria da GraçaMachado, Maria José2023-10-07T06:21:45Zoai:oai.revista.spmi.pt:article/2471Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:33:40.753842Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Fluoroquinolonas
title Fluoroquinolonas
spellingShingle Fluoroquinolonas
Morais Almeida, Maria da Graça
fluoroquinolonas
antimicrobia­nos
norfloxacina
ciprofloxacina
ofloxacina
pefloxacina
fluoroquinolones
antimicrobials
norfloxacin
ofloxacin
pefloxacin
ciprofloxacin
title_short Fluoroquinolonas
title_full Fluoroquinolonas
title_fullStr Fluoroquinolonas
title_full_unstemmed Fluoroquinolonas
title_sort Fluoroquinolonas
author Morais Almeida, Maria da Graça
author_facet Morais Almeida, Maria da Graça
Machado, Maria José
author_role author
author2 Machado, Maria José
author2_role author
dc.contributor.author.fl_str_mv Morais Almeida, Maria da Graça
Machado, Maria José
dc.subject.por.fl_str_mv fluoroquinolonas
antimicrobia­nos
norfloxacina
ciprofloxacina
ofloxacina
pefloxacina
fluoroquinolones
antimicrobials
norfloxacin
ofloxacin
pefloxacin
ciprofloxacin
topic fluoroquinolonas
antimicrobia­nos
norfloxacina
ciprofloxacina
ofloxacina
pefloxacina
fluoroquinolones
antimicrobials
norfloxacin
ofloxacin
pefloxacin
ciprofloxacin
description Fluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mecha­nism of action involves inhibition of bacterial DNA­ girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudo­monas aeruginosa and Staphilococcus sp., howe­ver recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The inci­dence of adverse effects to fluoroquinolones appe­ars to be low. The most common are gastrointesti­ nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occa­sionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifesta­tions, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of effi­cacity, when compared with IV administration, thus reducing substantially the treatment cost.
publishDate 1994
dc.date.none.fl_str_mv 1994-09-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/2471
url https://revista.spmi.pt/index.php/rpmi/article/view/2471
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/2471
https://revista.spmi.pt/index.php/rpmi/article/view/2471/1816
dc.rights.driver.fl_str_mv Direitos de Autor (c) 1994 Medicina Interna
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 1994 Medicina Interna
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.source.none.fl_str_mv Internal Medicine; Vol. 1 No. 3 (1994): Julho/ Setembro; 189-192
Medicina Interna; Vol. 1 N.º 3 (1994): Julho/ Setembro; 189-192
2183-9980
0872-671X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817550902168387584